| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Pharmacology Department, St. Jude Children's Research Hospital, Memphis, Tennessee 38105 [J. L. N.], and Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892 [P. P., Y. P.]
Aclacinomycin A (aclarubicin) is an anthracycline anticancer agent with demonstrated activity against both leukemias and solid tumors. Previous results suggested that a major activity of aclacinomycin A is the inhibition of topoisomerase II catalytic activity. We have applied a yeast system to test whether aclacinomycin A is a topoisomerase II inhibitor in vivo and to test whether we could identify other important targets of this drug. We have found that overexpression of yeast topoisomerase II confers resistance to aclacinomycin A in yeast, consistent with the hypothesis that this drug is a catalytic inhibitor of topoisomerase II. Interestingly, we have also found that in yeast, aclacinomycin A, like camptothecin, stabilizes topoisomerase I cleavage. We carried out biochemical analysis with purified human topoisomerase I and demonstrated that this drug efficiently stabilizes topoisomerase I covalent complexes, indicating that aclacinomycin A represents a novel class of combined topoisomerase I/II inhibitor.
1 This work was supported in part by NIH Grants CA52814 and CA21765 and by the American Lebanese Syrian Associated Charities.
2 To whom requests for reprints should be addressed, at Molecular Pharmacology Department, St. Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN 38105. Phone: (901) 495-2794; Fax: (901) 512-1668.
Received 6/17/97. Accepted 8/16/97.
This article has been cited by other articles:
|
|
 |
|
  M. Agostinho, V. Santos, F. Ferreira, R. Costa, J. Cardoso, I. Pinheiro, J. Rino, E. Jaffray, R. T. Hay, and J. Ferreira Conjugation of Human Topoisomerase 2{alpha} with Small Ubiquitin-like Modifiers 2/3 in Response to Topoisomerase Inhibitors: Cell Cycle Stage and Chromosome Domain Specificity Cancer Res., April 1, 2008; 68(7): 2409 - 2418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shiokawa, Y. Hattori, K. Kawano, Y. Ohguchi, H. Kawakami, K. Toma, and Y. Maitani Effect of Polyethylene Glycol Linker Chain Length of Folate-Linked Microemulsions Loading Aclacinomycin A on Targeting Ability and Antitumor Effect In vitro and In vivo Clin. Cancer Res., March 1, 2005; 11(5): 2018 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Joshi, Z. Wu, R. F. Reed, and D. P. Suttle Nuclear Factor-Y Binding to the Topoisomerase IIalpha Promoter Is Inhibited by Both the p53 Tumor Suppressor and Anticancer Drugs Mol. Pharmacol., February 1, 2003; 63(2): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Facompre, C. Carrasco, P. Colson, C. Houssier, J. D. Chisholm, D. L. Van Vranken, and C. Bailly DNA Binding and Topoisomerase I Poisoning Activities of Novel Disaccharide Indolocarbazoles Mol. Pharmacol., November 1, 2002; 62(5): 1215 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Khan, A. C. Nimrod, M. Mehrpooya, J. L. Nitiss, L. A. Walker, and A. M. Clark Antifungal Activity of Eupolauridine and Its Action on DNA Topoisomerases Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1785 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R van Gijn, R. Lendfers, J. Schellens, A Bult, and J. Beijnen Dual topoisomerase I/II inhibitors Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3): 92 - 108. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Pourquier, Y. Takebayashi, Y. Urasaki, C. Gioffre, G. Kohlhagen, and Y. Pommier Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells PNAS, February 15, 2000; 97(4): 1885 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Jensen, K. C. Nitiss, A. Rose, J. Dong, J. Zhou, T. Hu, N. Osheroff, P. B. Jensen, M. Sehested, and J. L. Nitiss A Novel Mechanism of Cell Killing by Anti-topoisomerase II Bisdioxopiperazines J. Biol. Chem., January 21, 2000; 275(3): 2137 - 2146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guano, P. Pourquier, S. Tinelli, M. Binaschi, M. Bigioni, F. Animati, S. Manzini, F. Zunino, G. Kohlhagen, Y. Pommier, et al. Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines Mol. Pharmacol., July 1, 1999; 56(1): 77 - 84. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Takebayashi, P. Pourquier, A. Yoshida, G. Kohlhagen, and Y. Pommier Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove PNAS, June 22, 1999; 96(13): 7196 - 7201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kohlhagen, K. D. Paull, M. Cushman, P. Nagafuji, and Y. Pommier Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison Mol. Pharmacol., July 1, 1998; 54(1): 50 - 58. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Pommier, G. Kohlhagen, P. Pourquier, J. M. Sayer, H. Kroth, and D. M. Jerina Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages PNAS, February 29, 2000; 97(5): 2040 - 2045. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
